← All trials
NCT04423380
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 14, 2020
- Primary completion
- Mar 31, 2021
- Completion date
- May 31, 2021
- First posted
- Jun 9, 2020
- Last posted
- Jun 9, 2020
- Enrollment
- 45
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nanjing Sanhome Pharmaceutical, Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.